Include EUS report and cytology, CEA, and amylase reports (IF NOT tested by Interpace Diagnostics).
Fax Requisition form and clinical reports to Interpace Diagnostics at
Expect a PancraGEN™ report delivered within 10 to 14 business days from the date of the requisition form (and sample, if applicable) submission.
AccuCEA is our highly accurate CEA method designed specifically for pancreatic cyst fluids and is especially convenient when used with PancraGEN.
The only CEA assay validated for use on small volumes (200uL) of cyst fluid.
Delivers accurate CEA measurements on pancreatic cyst fluids
Offers physicians more options – reserve cyst fluid for other diagnostic tests
Results reported within 1-3 business days
Al-Haddad MA, Kowalski T, Siddiqui A, et al. Integrated molecular pathology accurately determines the malignant potential of pancreatic cysts. Endoscopy. 2015;47(2):136-146.
V. Chernyak et al, Incidental pancreatic cystic lesions Radiology 2015 274 161-9
BU Wu, et al, Prediction of malignancy in cystic neoplasms of the pancreas: a population based cohort study, Am J Gastro 2014 109 121-9
Loren D, Kowalski T, Siddiqui A, et al. Influence of integrated molecular pathology test results on real-world management decisions for patients with pancreatic cysts: analysis of data from a national registry cohort. Diagnostic Pathology. 2016;11:5. doi:10.1186/s13000-016-0462-x.
Gaujoux S., , Brennan, M., et al. Cystic Lesions of the Pancreas: Changes in the Presentation and Management of 1,424 Patients at a Single Institution over a 15-year Time Period. J Am Coll Surg. 2011 April; 212(4): doi:10.1016/j.jamcollsurg.2011.01.016.
Kaimalkliotis, P., Riff, B., et al. Sendai and Fukuoka Consensus Guidelines Identify Advanced Neoplasia in Patients With Suspected Mucinous Cystic Neoplasms of the Pancreas. Clinical Gastroenterology and Hepatology 2015;13:1808–1815: doi:10.1016/j.cgh.2015.03.017